Outlook Therapeutics, Inc.
NASDAQ:OTLK
1.47 (USD) • At close December 24, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 8.146 | 3.088 | 3.812 | 2.98 | 5.219 | 9.051 |
| Cost of Revenue
| 0.044 | 0.205 | 0.262 | 0.554 | 0.024 | 0.019 | 0.024 | 0.033 | 0.039 | 0.014 |
| Gross Profit
| -0.044 | -0.205 | -0.262 | -0.554 | 8.122 | 3.069 | 3.788 | 2.947 | 5.18 | 9.036 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0.997 | 0.994 | 0.994 | 0.989 | 0.993 | 0.998 |
| Reseach & Development Expenses
| 26.453 | 42.331 | 38.958 | 26.342 | 23.805 | 18.504 | 23.81 | 32.763 | 38.876 | 14.125 |
| General & Administrative Expenses
| 26.673 | 20.74 | 12.769 | 9.971 | 9.37 | 14.228 | 15.882 | 21.636 | 12.906 | 7.318 |
| Selling & Marketing Expenses
| 0 | 0 | 0.28 | -1.896 | -3.847 | -7.254 | -2.692 | -2.467 | 0 | 0 |
| SG&A
| 26.673 | 20.74 | 13.049 | 8.075 | 5.523 | 6.973 | 13.19 | 19.169 | 12.906 | 7.318 |
| Other Expenses
| 0 | -0.883 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 53.126 | 63.071 | 51.727 | 36.313 | 29.328 | 25.478 | 39.692 | 51.932 | 51.782 | 21.443 |
| Operating Income
| -53.126 | -63.071 | -51.727 | -36.841 | -36.299 | -25.444 | -35.88 | -51.758 | -46.563 | -12.392 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | -4.456 | -8.241 | -9.414 | -17.371 | -8.921 | -1.369 |
| Total Other Income Expenses Net
| -5.853 | -2.979 | -1.435 | -1.671 | -1.636 | -4.096 | -2.467 | -1.852 | -2.297 | -0.901 |
| Income Before Tax
| -58.98 | -66.049 | -53.161 | -38.511 | -37.935 | -33.74 | -38.348 | -53.226 | -48.86 | -13.293 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | -4.657 | -10.928 | -10.061 | -17.864 | -9.362 | -1.469 |
| Income Tax Expense
| 0.003 | 0.003 | 0.002 | -3.272 | -3.411 | -3.648 | 0.502 | 0.103 | -0.19 | 0.439 |
| Net Income
| -58.983 | -66.052 | -53.163 | -35.239 | -34.524 | -46.115 | -38.849 | -53.329 | -47.393 | -13.732 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | -4.238 | -14.936 | -10.193 | -17.898 | -9.081 | -1.517 |
| EPS
| -4.72 | -6.23 | -6.96 | -9.71 | -37.96 | -50.7 | -258.75 | -495.71 | -504.47 | -155.35 |
| EPS Diluted
| -4.72 | -6.23 | -6.96 | -9.71 | -37.96 | -50.7 | -258.54 | -495.71 | -504.47 | -155.35 |
| EBITDA
| -57.376 | -62.866 | -51.465 | -35.759 | -31.106 | -26.795 | -30.03 | -48.953 | -44.738 | -11.514 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | -2.66 | -7.252 | -8.707 | -16.567 | -8.572 | -1.272 |